ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
127.668,61
-1,73%
S&P 500
5.998,74
-0,38%
US Dollar vs BRL
5,9377
-0,02%
Bitcoin
95.432,26
-0,57%
Brent Oil
72,185
-0,29%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. GlycoMimetics Inc (GLYC)

  7. GlycoMimetics Inc (GLYC) Notícias

GLYC

GlycoMimetics (GLYC)

GlycoMimetics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:GLYC
DataHoraFonteTítuloCódigoCompanhia
27/11/202416:22Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:GLYCGlycoMimetics Inc
12/11/202410:00PR Newswire (US)Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024NASDAQ:GLYCGlycoMimetics Inc
07/11/202418:47Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:GLYCGlycoMimetics Inc
07/11/202418:42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLYCGlycoMimetics Inc
06/11/202409:00Business WireGlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual MeetingNASDAQ:GLYCGlycoMimetics Inc
04/11/202418:26Edgar (US Regulatory)Form SC 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:GLYCGlycoMimetics Inc
04/11/202416:01Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:GLYCGlycoMimetics Inc
29/10/202411:00AllPennyStocks.comBiotech Up Over +100% Premarket Following Merger And Funding AnnouncementNASDAQ:GLYCGlycoMimetics Inc
29/10/202411:00AllPennyStocks.comShares of Biotech Company Up Over 100% Premarket Following Merger & Funding AnnouncementNASDAQ:GLYCGlycoMimetics Inc
29/10/202408:00Business WireGlycoMimetics Enters Into Acquisition Agreement With Crescent BiopharmaNASDAQ:GLYCGlycoMimetics Inc
29/10/202407:30Business WireGlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary EndpointNASDAQ:GLYCGlycoMimetics Inc
15/08/202418:01Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:GLYCGlycoMimetics Inc
14/08/202417:13Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:GLYCGlycoMimetics Inc
08/08/202417:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GLYCGlycoMimetics Inc
25/07/202410:00Business WireGlycoMimetics Announces Strategic Review and Corporate Restructuring PlanNASDAQ:GLYCGlycoMimetics Inc
04/06/202408:00Business WireGlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)NASDAQ:GLYCGlycoMimetics Inc
29/05/202417:01Business WireGlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024NASDAQ:GLYCGlycoMimetics Inc
06/05/202407:00Business WireGlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)NASDAQ:GLYCGlycoMimetics Inc
25/04/202408:00Business WireGlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024NASDAQ:GLYCGlycoMimetics Inc
27/03/202408:00Business WireGlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023NASDAQ:GLYCGlycoMimetics Inc
13/03/202408:00Business WireGlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024NASDAQ:GLYCGlycoMimetics Inc
26/02/202409:00Business WireGlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care ConferenceNASDAQ:GLYCGlycoMimetics Inc
12/02/202409:00Business WireGlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:GLYCGlycoMimetics Inc
17/01/202418:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLYCGlycoMimetics Inc
04/01/202409:00Business WireGlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687NASDAQ:GLYCGlycoMimetics Inc
03/01/202409:00GlobeNewswire Inc.Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid LeukemiaNASDAQ:GLYCGlycoMimetics Inc
10/12/202314:00Business WireGlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid LeukemiaNASDAQ:GLYCGlycoMimetics Inc
09/11/202309:00Business WireGlycoMimetics to Participate in Upcoming Jefferies London Healthcare ConferenceNASDAQ:GLYCGlycoMimetics Inc
03/11/202308:00Business WireGlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023NASDAQ:GLYCGlycoMimetics Inc
23/10/202309:30PR Newswire (US)Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory BoardNASDAQ:GLYCGlycoMimetics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:GLYC

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
RCSL4
RECRUSUL PN
BOV
BHIA3
Grupo Casas Bahia ON
BOV
TELB4
TELEBRAS PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Economize até 60%* para TRADER PLUS

1 ano 40%, 2 anos 50% e *3 anos 60%

*Ao longo de 3 anos $ 1475.65 apenas $ 590.25